Fig. 1: Treatment-emergent all-grade AEs occurring in ≥ 30% of patients in any arm.^a

ASC asciminib, DAS dasatinib, IMA imatinib, NIL nilotinib. ^aAEs were counted if they occurred after treatment initiation through 30 days after the end of treatment.